Access the latest scientific news and research when and where you want it. Download the latest issues to browse at your convenience, zoom in on figures and images, save your searches and synchronize your bookmarks across devices.
No end in sight for telomerase-targeted cancer drugs doi:10.1038/nm0113-6 Recent clinical trials are providing evidence that telomerase inhibitors might be an effective cancer treatment, at least when it comes to some tumor types. Full Text
As leukemia options grow, drugs jockey to be first-line therapies doi:10.1038/nm0113-7 The recent approval of Ponatinib offers hope to patients who are intolerant to other tyrosine kinase inhibitors, or whose cancer cells have evolved resistance to these. Full Text
Neglected diseases see few new drugs despite upped investment doi:10.1038/nm0113-2 A new analysis finds that although the rate of approvals has gone up, the rate of approvals for new chemical entities seems to have remained relatively flat. Full Text
An Audience With: Luca Santarelli doi:10.1038/nrd3925 The Senior Vice President and Head of Neuroscience Research and Early development at Roche discusses why Roche has stayed firmly committed to research and development for central nervous system disorders. Full Text
HER2's new mutations doi:10.1038/scibx.2013.26 Researchers have used next-generation sequencing to identify mutations in HER2 that are missed by standard screening tests, and are now recruiting patients with breast cancer expressing the mutations for a Phase II trial of Puma's HER2-targeting compound, neratinib. Full Text
Alzheimer's disease market: hope deferred doi:10.1038/nrd3922 The last few months have seen a flurry of trial results for investigational agents in Alzheimer's disease. This analysis investigates the different categories of developmental drugs, and provides an outlook to the future of the market. Full Text
Lung disorders: A new model and modulator of pulmonary oedema doi:10.1038/nrd3917 Two complementary studies have identified a new microdevice model — termed 'lung on a chip' — of pulmonary oedema, and identified a blocker of TRPV4 that inhibits pulmonary oedema in animal models. Full Text
Immunotherapy: Immunological bullets against Alzheimer's disease doi:10.1038/nrd3919 The exact contribution of innate immune signalling to Alzheimer’s disease pathogenesis is still unclear. Now, researchers have identified IL-12 and IL-23 signalling as a therapeutic target in this neurodegenerative disorder. Full Text
Neurological disorders: Targeting translation in autism doi:10.1038/nrd3915 A study in Nature shows that pharmacological inhibition of eIF4E activity or siRNA-mediated knockdown of neuroligin 1 are novel potential targets for the treatment of Autism Spectrum Disorders. Full Text
Objective assessment of cancer genes for drug discovery doi:10.1038/nrd3913 This article describes and demonstrates an objective, systematic computational assessment of biological and chemical space. The approach can be applied to any human gene set to prioritize targets for further evaluation. Full Text
Kynurenines in the CNS: recent advances and new questions doi:10.1038/nrd3793 This Review describes the role of the kynurenine pathway in the pathology of Huntington's disease, migraine and multiple sclerosis, and highlights the most promising compounds that could be of therapeutic value. Full Text
Ablation of TRIP-Br2, a regulator of fat lipolysis, thermogenesis and oxidative metabolism, prevents diet-induced obesity and insulin resistance doi:10.1038/nm.3056 As expression of TRIP-Br2 is elevated in fat from obese humans, TRIP-Br2 might be a new therapeutic target against insulin resistance and hyperlipidemia. Full Text
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets doi:10.1038/nm.3048 The authors have engineered anti-BCL drugs to reduce platelet toxicity. Their compound is effective in several tumor models in vivo and had reduced toxicity in three patients with refractory leukemia. Full Text
Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text
SciBX: Science-Business eXchange is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why.
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant)
Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA
Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston
Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS.
No comments:
Post a Comment